Better Therapeutics to Participate in Two Upcoming Investor Events
January 20 2022 - 4:00PM
Business Wire
Better Therapeutics, Inc. (“Better
Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics
(PDT) company developing cognitive behavioral therapy to address
root causes of cardiometabolic diseases, today announced that Kevin
Appelbaum, Chief Executive Officer, is scheduled to participate in
two upcoming investor events as follows:
- A virtual fireside chat hosted by LifeSci Capital on January 26
from 12 – 1 p.m. EST. The management team will discuss the current
treatment paradigm for cardiometabolic diseases, Better
Therapeutics’ approach for treating behavioral root causes using
prescription digital therapeutics (PDT), and its lead candidate
BT-001, a PDT for treating uncontrolled type 2 diabetes in adults,
currently undergoing a potentially pivotal trial. To register for
the call, please email Robert Fromberg
(rfromberg@lifescicapital.com).
- The Cowen 42nd Annual Health Care Conference taking place March
7 – 9 in Boston, MA, including a fireside chat on Monday, March
7th, from 2:10-2:40 pm EST.
- A replay of both firesides will be available on the
Presentations and Events section on the Better Therapeutics
investor site (www.investors.bettertx.com) for approximately 90
days after the event.
About Better Therapeutics
Better Therapeutics is a
prescription digital therapeutics (PDT) company developing a novel
form of cognitive behavioral therapy to address the root causes of
cardiometabolic diseases. The company has developed a proprietary
platform for the development of FDA-regulated, software-based
solutions for type 2 diabetes, heart disease and other conditions.
The cognitive behavioral therapy delivered by Better Therapeutics’
PDT is designed to enable changes in neural pathways of the brain
so lasting changes in behavior become possible. Addressing the
underlying causes of these diseases has the potential to
dramatically improve patient health while lowering healthcare
costs. Better Therapeutics clinically validated mobile applications
are intended to be prescribed by physicians and reimbursed like
traditional medicines. For more information visit: bettertx.com
BTTX-PR
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220120005817/en/
Investor Relations: Mark Heinen IR@bettertx.com
Media: Cassidy McClain Cassidy.McClain@canalecomm.com
619.849.6009
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Apr 2023 to Apr 2024